Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients
| Autor: | Elisa Singh, Oleg V. Kopyov, Anthony Bravo, Benjamin Rapaport, Michael Arata, Ami R Sanathara, Kristin Scord, Sawyer Farmer, Chad A. Caraway, Sean Berman, Mark Berman, Michael Elam, Ruslana Cannell, Rory McRory, Alex Kopyov, Christian Yassa, Christopher Duma, Samuel Khoudari, Karlyssa Chung, Lian Stemler, David Weiland, Elliot B Lander, Chace Duma |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Traumatic brain injury Adipose tissue Mesenchymal Stem Cell Transplantation Transplantation Autologous Ventriculoperitoneal Shunt 03 medical and health sciences 0302 clinical medicine Genetics medicine Humans Amyotrophic lateral sclerosis Molecular Biology Stroke Spinal cord injury Dexamethasone Aged Aged 80 and over business.industry Multiple sclerosis Hematopoietic Stem Cell Transplantation Neurodegenerative Diseases General Medicine Middle Aged Stromal vascular fraction Hematopoietic Stem Cells medicine.disease Infusions Intraventricular Treatment Outcome 030104 developmental biology Adipose Tissue 030220 oncology & carcinogenesis Anesthesia Female business medicine.drug |
| Zdroj: | Molecular Biology Reports. 46:5257-5272 |
| ISSN: | 1573-4978 0301-4851 |
| DOI: | 10.1007/s11033-019-04983-5 |
| Popis: | We have chosen to test the safety of human intracerebroventricular (ICV) brain injections of autologous non-genetically-modified adipose-derived stromal vascular fraction (ADSVF). In this IRB-approved trial, 24 patients received ICV ADSVF via an implanted reservoir between 5/22/14 and 5/22/17. Seven others were injected via their ventriculo-peritoneal shunts. Ten patients had Alzheimer’s disease (AD), 6 had amyotrophic lateral sclerosis (ALS), 6 had progressive multiple sclerosis (MS-P), 6 had Parkinson’s “Plus” (PD+), 1 had spinal cord injury, 1 had traumatic brain injury, and 1 had stroke. Median age was 74 (range 41–83). Injections were planned every 2–3 months. Thirty-one patients had 113 injections. Patients received SVF injection volumes of 3.5–20 cc (median:4 cc) containing 4.05 × 105 to 6.2 × 107 cells/cc, which contained an average of 8% hematopoietic and 7.5% adipose stem cells. Follow-up ranged from 0 to 36 months (median: 9.2 months). MRIs post injection(s) were unchanged, except for one AD patient whose hippocampal volume increased from |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink